OVID THERAPEUTICS INC.

Analyst Reco. Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.15 ^USD	-1.56%		-0.63%	-2.17%

Mar. 08	Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 08	Earnings Flash (OVID) OVID THERAPEUTICS Reports Q4 Revenue $141,562	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Initiates Ovid Therapeutics With Buy Rating, Price Target is $11	Dec. 21	MT
Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target	23-10-13	MT
JonesTrading Initiates Ovid Therapeutics at Buy With $6 Price Target	23-06-14	MT
Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating	22-05-20	MT
OVID THERAPEUTICS : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Keeps Neutral Rating	21-08-25	MT
OVID THERAPEUTICS : Cantor Fitzgerald Downgrades Ovid Therapeutics to Neutral from Overweight, Adjusts PT to $4 from $8	21-04-20	MT
OVID THERAPEUTICS : RBC Cuts Price Target on Ovid Therapeutics to $4 From $5, Maintains Rating at Sector Perform, Speculative Risk	21-04-20	MT
OVID THERAPEUTICS : Ladenburg Thalmann Adjusts Price Target on Ovid Therapeutics to $7 From $21, Maintains Buy Rating	20-12-02	MT
OVID THERAPEUTICS : RBC Capital Adjusts Ovid Therapeutics PT to $5 From $17, Maintains Outperform - Speculative Risk Rating	20-12-02	MT
OVID THERAPEUTICS : Citigroup Downgrades Ovid Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $10	20-12-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer